Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

Xijuan Lin, Ziwei Liu, Chen Yang, Junling Zhuang, Na Wei, Tingting Cui, Wenqi Zheng, Fang Ye, Xiaoqing Ding, Miao Chen, Bing Han

Blood (2025) 146 (Supplement 1): 5624.

https://doi.org/10.1182/blood-2025-5624

Published: 2025

Journal Articles

Real-world outcomes with eliglustat for gaucher disease type 1 in China: A multicenter retrospective study

Yongxin Zhou, Zijian Hao, Zhuang Qilin, Miao Chen, Junling Zhuang, Bing Han

Blood (2025) 146 (Supplement 1): 7980.

https://doi.org/10.1182/blood-2025-7980

Published: 2025

Journal Articles

Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study

Miao Chen, Ziwei Liu, Chen Yang, Junling Zhuang, Bing HAN

Blood (2025) 146 (Supplement 1): 1104.

https://doi.org/10.1182/blood-2025-1104

Published: 2025

Journal Articles

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single‑center study

Zhuang Qilin, Ziwei Liu, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2025) 146 (Supplement 1): 1416.

https://doi.org/10.1182/blood-2025-1416

Published: 2025

Journal Articles

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Yian Zhang, Bingzong Li, Junling Zhuang, Pengcheng He, Xingli Zhao, Baijun Fang, Songfu Jiang, Bing Chen, Zhongjun Xia, Zhenyu Li, Zengjun Li, Haifeng Zhao, Dawei Ding, Qianqian Zhang, Xunqiang Wang, Peng Liu

Blood (2025) 146 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2025-2279

Published: 2025

Journal Articles

Treatment with sirolimus for refractory/relapsed primary or secondary warm autoimmune hemolytic anemia/evans syndrome: A single centre prospective study

Qi Wang, Miao Chen, Junling Zhuang, Chen Yang, ziwei liu, Bing Han

Blood (2025) 146 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2025-4666

Published: 2025

Journal Articles

High-throughput single-cell lipidomics reveals stage-specific phospholipid remodeling and ferroptosis-related signatures in the Evolution of plasma cell dyscrasia

Fujing Zhang, Chenxi Cao, Junling Zhuang, Peng Liu, Xiaoxiao Ma

Blood (2025) 146 (Supplement 1): 7458.

https://doi.org/10.1182/blood-2025-7458

Published: 2025

Journal Articles

The Role of Next-Generation Sequencing in Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with VRD Regimen

Lili Cheng, Fujing Zhang, Ziping Li, Junling Zhuang, Hao Cai, Hui Li

Blood (2024) 144 (Supplement 1): 6856.

https://doi.org/10.1182/blood-2024-210092

Published: 2024

Journal Articles

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Zhuxin Zhang, Leyu Wang, Ziwei Liu, Chen Yang, Miao Chen, Bing Han, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6730.

https://doi.org/10.1182/blood-2024-199403

Published: 2024

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Hong Yu, Aijun Liu, Wei Wang, Xiaoqi Qin, Ziping Li, Yanping Ma, Wenming Chen, Rong Fu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 7038.

https://doi.org/10.1182/blood-2024-210284

Published: 2024

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Xijuan Lin, Chen Yang, Ziwei Liu, Junling Zhuang, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2024-200421

Published: 2024

Journal Articles

YM155 Exerts Anti-Myeloma Effects Via Myc/BBC3 Signaling Pathway in Vitro

Xianghong Jin, Fujing Zhang, Huiwen He, Ziping Li, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6849.

https://doi.org/10.1182/blood-2024-205692

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Peng Liu, Junling Zhuang, Zhongjun Xia, Bingzong Li, Songfu Jiang, Yian Zhang, Wei Wang, Xiaoqin Chen, Xiaohui Zhang, Shujuan Zhou

Blood (2024) 144 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2024-209665

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

Yuhang Song, Yang Liu, Junru Liu, Juan Li, Jin Lu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 4679.

https://doi.org/10.1182/blood-2024-206458

Published: 2024

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Rong Fu, Wenming Chen, Wei Wang, Yanping Ma, Junling Zhuang

Blood (2023) 142 (Supplement 1): 6696.

https://doi.org/10.1182/blood-2023-187828

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

Real-world outcomes with eliglustat for gaucher disease type 1 in China: A multicenter retrospective study

Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single‑center study

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Treatment with sirolimus for refractory/relapsed primary or secondary warm autoimmune hemolytic anemia/evans syndrome: A single centre prospective study

High-throughput single-cell lipidomics reveals stage-specific phospholipid remodeling and ferroptosis-related signatures in the Evolution of plasma cell dyscrasia

The Role of Next-Generation Sequencing in Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with VRD Regimen

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

YM155 Exerts Anti-Myeloma Effects Via Myc/BBC3 Signaling Pathway in Vitro

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only